摘要
[目的]探讨唯美生放射免疫治疗联合射频消融治疗原发性肺癌的疗效及血液学毒性。[方法]选取2009年8月到2011年2月原发性肺癌患者13例,均经6个疗程以上化疗,临床评估认为继续化疗不能获益者。患者在CT引导下进行肿瘤局部射频消融治疗,术中唯美生瘤内注射,剂量按29.6MBq/kg给予。[结果]治疗后2d,唯美生全身放射免疫显像,所有患者病灶部位均有不同程度唯美生浓聚。治疗后1个月,白细胞明显下降(t=0.1887,P=0.0142),血小板有轻度下降(t=0.8334,P=0.3872)。治疗后3个月,胸部CT示,CR3例、PR2例、SD4例、PD4例,总缓解率(CR+PR)38.46%(5/13),疾病控制率(CR+PR+SD)69.23%(9/13)。[结论]唯美生放射免疫治疗联合射频消融治疗原发性肺癌疗效较好,毒副反应较轻。
[Purpose] To investigate the efficacy and hematological toxicity of iodine-131-labeled chimeric tumor necrosis treatment（131I-chTNT） radioimmunotherapy combined with radiofrequency catheter ablation（RAF） in the treatment of patients with primary lung cancer.[Method] Thirteen cases with primary lung cancer（from August 2008 to February 2011） were enrolled,all patients had experienced more than six cycles chemotherapy,clinical assessment that cannot continue to benefit from chemotherapy.The RAF treatment was carried out at the local tumor under CT guided,and 131I-chTNT was intratumoral injected directly with a dose of 29.6MBq/kg.[Results] Two days after 131I-chTNT treatment,131I-chTNT could be found with tumor lesions in whole body radioimmunoimaging in all patients.One month after treatment,the white blood cells count was decreased significantly compared with pre-treatment（t=0.1887,P=0.0142）.While the blood platelet count decreased slightly compared with pre-treatment,but there was no significant different（t=0.8334,P=0.3872）.Three months after treatment,chest CT showed 3 cases in CR,2 in PR,4 in SD and 4 in PD.The response rate（CR＋PR） was 38.46%（5/13）,disease control rate（CR＋PR＋SD） was 69.23%（9/13）.[Conclusion] 131I-chTNT radioimmunotherapy combined with RAF for patients with primary lung cancer is effective with mild toxicity.
出处
《肿瘤学杂志》
CAS
2011年第12期920-922,共3页
Journal of Chinese Oncology
基金
卫生部医药卫生科技发展研究中心课题(W2011BX072)
关键词
肺肿瘤
唯美生放射免疫治疗
射频消融
lung neoplasm
131I-chTNT radioimmunotherapy
radiofrequency catheter ablation
